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A novel quadrupole ion trap mass spectrometer laser microprobe instrument with an external
ionization source was constructed and used to investigate the matrix-assisted laser desorp-
tion/ionization (MALDI) detection of pharmaceutical compounds in intact tissue. In addition
to MALDI, laser desorption coupled with chemical ionization (LD/CI) was investigated.
MALDI, using 2,5-dihydroxybenezoic acid (DHB) as a matrix, was employed to detect the
anticancer drug paclitaxel from a thin section of rat liver tissue which had been incubated in
a solution of paclitaxel. The results of that experiment showed that the ability to perform
tandem mass spectrometry (MS/MS) with the quadrupole ion trap was crucial in the
identification of drug compounds at trace levels in the complex tissue matrix. MALDI MS/MS
was then used to detect the presence of paclitaxel in a human ovarian tumor at a concentration
of approximately 50 mg/kg. Finally, the drug spiperone was detected in incubated rat liver
tissue at an approximate level of 25 mg/kg using LD/CI (no MALDI matrix). Again, the
MS/MS capability of the quadrupole ion trap was crucial in the identification of the drug at
trace levels in the complex tissue matrix. (J Am Soc Mass Spectrom 1999, 10,
1315–1321) © 1999 American Society for Mass Spectrometry
There are several chemical attributes that are im-portant in pharmaceutical research and develop-ment when selecting a lead compound for devel-
opment, including receptor/enzyme specificity,
adequate potency, and lack of toxicity in the therapeutic
range. A significant, if not the most significant, factor
however, is the availability of the agent at the site of
action. Traditionally, in vitro cell-based assays have
been used to determine the binding efficiency of a drug
with a receptor site. These types of screens can give a
good indication of a drugs’ activity, but they do not
indicate whether or not the drug will be transported to
the disease target. Conversely, metabolic profiling of
bodily fluids using standard analytical techniques
(chromatography, NMR, and mass spectrometry cou-
pled with chromatography) can determine the systemic
bioavailability of a specific drug compound, but pro-
vides limited information regarding the penetration of
the drug into the tissues in either the intracellular
and/or extracellular spaces. To determine whether a
drug reaches its site of action and the chemical structure
of the drug at that location requires microprobe tech-
niques with high sensitivity and good spatial resolu-
tion. The combination of a laser microprobe for high
spatial resolution sampling coupled with mass spec-
trometry for high sensitivity should make a powerful
investigative tool for pharmaceutical research and de-
velopment.
Paclitaxel is an anticancer drug from the Taxus
alkaloid family of products found in the Pacific yew tree
bark [1]. Paclitaxel functions as an anticancer drug by
stabilizing microtubules (composed of tubulin) during
cell division (mitosis) [2]. Although the function of
paclitaxel is well known, there is a great deal of interest
in how paclitaxel is delivered to and how it attacks the
living tumor. Clinical studies indicate that paclitaxel
first binds (reversibly, with low affinity) to plasma
proteins [3]. The paclitaxel is then cleared from the
blood and delivered to the tissue (including the tumor).
As the outer layers of the tumor die away due to the
paclitaxel, the vascular region surrounding the tumor
contracts. This suggests that the paclitaxel is only de-
livered to the outer layers of the tumor. One of the long
term goals of this research is to elucidate the delivery
location of paclitaxel in a human cancer tumor.
The use of a laser beam to desorb target compounds
in a microprobe instrument was a logical selection.
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Lasers allow for a wide variety of spot sizes to be used
(from greater than 1 cm to smaller than 1 mm in
diameter depending on the laser) and a wide variety of
power densities (usually in the 106 to 1010 W/cm2
range) capable of producing a large number of gas-
phase neutrals and ions from many thermally labile and
nonvolatile compounds. The first laser microprobe in-
struments were developed in the 1960’s and were used
primarily for mapping surfaces to determine elemental
composition [4–6]. Since then, the laser microprobe has
been utilized on more diverse samples, ranging from
geological specimens to human teeth [7–11]. In recent
years microprobe instruments have been developed
using secondary ion mass spectrometry (SIMS) as the
desorption technique. These SIMS microprobe instru-
ments have demonstrated excellent spatial resolution
(in the 0.1 to 10 mm diameter range) [12]. However,
laser-based microprobes have the advantage over SIMS
of being able to probe deeper into and in fact through a
tissue sample [13]. An additional advantage of using
laser desorption is the need for little or no sample
preparation [14–17]. In the case of tissue samples exam-
ined in our lab, the tissue was simply sliced thin while
frozen and placed onto a probe tip. Those samples
examined by MALDI had the added step of a matrix
being applied before drying, while samples examined
by LD/CI were allowed to dry undisturbed.
Commercial laser microprobe mass analyzer
(LAMMA) instruments are available and have tradi-
tionally been time-of-flight (TOF) instruments. TOF
instruments give the user a theoretically unlimited
mass-to-charge range as well as a high transmission of
ions, and have recently demonstrated a spatial resolu-
tion of 850 dots per inch [18]. However, TOF instru-
ments cannot readily provide tandem mass spectromet-
ric capabilities (MS/MS and MSn) with the parent ion
selection and fragmentation capabilities of an ion trap.
This limitation of TOF instruments leads to substantial
interferences when examining trace-level compounds in
a complex matrix such as tissue [19]. In our studies, we
have found the ability to perform MS/MS to be essen-
tial for the positive identification of a target compound
in tissue.
In recent years microprobe instruments have been
developed utilizing triple-quadrupole and Fourier
transform ion cyclotron resonance (FTICR) mass spec-
trometers [12, 13]. Although both of these mass spec-
trometry techniques have the capability of performing
MS/MS to aid in the identification of trace level com-
pounds in tissue, both have drawbacks which make the
quadrupole ion trap more attractive. MS/MS on the
triple-quadrupole suffers from ion transmission losses
and a temporal mismatch between the pulsed desorp-
tion of ions and the time required to scan the mass
filters [12]. Fourier transform instruments are capable of
MS/MS; however, the low pressures needed for accu-
rate detection of ions coupled with the relatively high
pressures needed for collisionally activated dissociation
(CAD), result in an added level of difficulty above that
of the quadrupole ion trap [20]. We are unaware of any
example of trace-level determination of organic ana-
lytes in complex matrices such as tissue with these
instruments.
It was with the above considerations in mind that we
constructed a custom laser microprobe quadrupole ion
trap instrument designed to provide not only the spatial
resolution needed to determine the location of a drug
compound within a tissue sample, but also the power of
MSn needed to resolve the target compound from the
background tissue matrix.
Experimental
Instruments
Most experimental results presented here were ob-
tained on a quadrupole ion trap instrument constructed
at the University of Florida specifically for the analysis
of drug compounds in tissue. The instrument consists of
a Finnigan 4500 EI/CI ion source from Finnigan MAT
(San Jose, CA) coupled via a dc quadrupole deflector to
a Finnigan ITS-40 ion trap mass analyzer housed in a
differentially pumped, cradle-type vacuum chamber
(Figure 1). One of the advantages of this ion source is
that the ion volume can be changed with each sample to
minimize carry-over effects. The only modification to
the ion source was the blocking of the GC transfer line
inlet hole so that a sufficient pressure of CI reagent gas
(methane for this study) could be obtained for the
LD/CI studies. The ion source and probe lock were
mounted 90° in relation to the ion trap to allow the laser
beam to be introduced into the source orthogonal to the
probe face. This design assured that a small laser spot
size with high power density could be obtained and
that the ions would be desorbed in the direction of the
ion extraction and focusing lenses. Additionally, the 90°
Figure 1. Drawing (not to scale) of the ion trap laser microprobe
instrument. Note that the laser beam enters orthogonal to the
probe surface and the ions are turned 90° by the dc quad deflector
to enter the ion trap.
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design allows for future modifications to the instrument
that will permit the viewing of the sample for laser
desorption position selection. To direct the ions from
the ion source to the ion trap, a dc quadrupole was used
as a 90° ion deflector as described by Pedder and Yost
[21].
Initial MALDI experiments with the drug paclitaxel
in rat liver tissue were performed on an earlier version
of the ion trap laser microprobe instrument similar to
that described above [22]. The only significant differ-
ences were the source used [a modified commercial
Vestec (Houston, TX) MALDI-TOF source in the earlier
version] and the addition of the 90° ion deflector in the
later version. Because of the configuration of the source,
the angle of incidence of the laser beam on the probe tip
was approximately 45°. In addition, the openess of the
Vestec MALDI-TOF source made achieving proper CI
pressures impossible. For this reason the new ion trap
laser microprobe instrument was constructed and used
for all further studies. The differences between the
instruments had no effect on the conclusions drawn
from the data presented here.
A UV laser was used for all MALDI experiments.
The UV laser was a Laser Science (Cambridge, MA)
model VSL-337ND pulsed nitrogen laser with a wave-
length of 337.1 nm and a 3 ns pulse width (full width at
half maximum). The maximum energy output was
.250 mJ/pulse with a peak power of 85 kW. The laser
beam’s intensity was adjusted between 106 and 107
W/cm2 using a wheel attenuator (Newport Corp., Ir-
vine, CA). The position of the laser beam was adjusted
manually with an x, y, z micromanipulator attached to
the beam deflector (Newport). The laser was near-
diffraction limited, which allowed the beam to be more
easily focused to a tight spot. The beam size employed
for these studies was estimated to be a circle with a
diameter of 100 mm. The spot size may be considered
large for microprobe instruments; however, the pur-
pose of our preliminary investigations was not to min-
imize the laser spot size. For any microprobe instru-
ment, there is a tradeoff between sensitivity and spatial
resolution. To detect trace level compounds a sufficient
amount of matrix/analyte must be desorbed in order to
produce enough analyte ions for mass analysis and
detection. Published applications of previous micro-
probe instruments have generally not dealt with anal-
ysis at trace levels, but rather have focused on spatial
resolution.
LD/CI experiments used a Lumonics (Ontario, Can-
ada) series TE-860-4 excimer CO2 IR laser with a wave-
length of 10.6 mm and a maximum energy output of 6 J
per pulse (here typically 2.6 J per pulse) with a pulse
duration of 2 ns to 1.5 ms. The beam size of the IR laser
was reduced by physical blocking from a 25 3 13 mm
rectangular spot down to a round spot with a diameter
of 4 mm before focusing. The physical blocking reduced
the energy per pulse used in these experiments to
approximately 115 mJ (assuming an even energy distri-
bution across the beam and simple reduction in beam
size). The spot size after focusing had a diameter of 750
mm, making the power density approximately 4 3 107
W/cm2.
The lasers were focused into the mass spectrometer
chamber by a single focusing lens (Melles-Griot, Irvine,
CA) with a focal length of 25.4 cm (fused silica for UV
and zinc-selenide for IR). The lasers were externally
triggered after a 1 ms delay by a Wavetek (Indianapolis,
IN) model 275 function generator to insure that the ion
source gate had fully opened before ionization.
The software (Gatorware) used to control the scan
and acquisition of the ITS-40 was written by Tim Griffin
and Nathan Yates at the University of Florida [23, 24].
Additionally, a Stanford Research Systems (Sunnyvale,
CA) synthesized function generator model DS345 was
used to generate the stored waveform inverse Fourier
transform (SWIFT) waveforms used for waveform iso-
lation of ions in the ion trap during LD/CI experiments
[25]. The waveforms were created with a computer
program which was written at the University of Florida
by Peter Palmer which created isolation waveforms
similar to those described in a paper by Chen et al. [25].
Solvents and chemicals used in these experiments
(with the exception of the paclitaxel) were purchased
from the Sigma Chemical (St. Louis, MO).
Sample Preparation
A whole liver was obtained from a male Sprague-
Dawley rat after sacrifice. The liver tissue was directly
transferred to storage in a 220 °C freezer. For MALDI
experiments, the liver tissue was thinly sliced (approx-
imately 0.5 mm thick) while frozen and a 2.0 mg section
was incubated for 1 hour in 1.0 mL of methanol solution
which contained approximately 100 ng of paclitaxel.
The tissue was removed and washed with several drops
of deionized water before being placed on a stainless
steel probe tip and allowed to dry. 1–2 mL of a 0.1 M
DHB matrix in methanol was pipetted onto the surface
of the liver tissue and allowed to dry completely before
analysis.
The ovarian cancer tumor was obtained from Bristol-
Myers Squibb Oncology Division (Princeton, NJ). The
tumor was human in origin but had been implanted
and grown to size (approximately 10 mm in diameter)
in an immunodeficient, nude mouse. The mouse was
administered the paclitaxel in a 10% cremphor, 10%
ethanol, 80% saline solution intravenously. The concen-
tration of paclitaxel in the tumor was reported by
Bristol-Myers Squibb to be 10–50 mg/kg of tumor.
Approximately 1 h after administration of the drug
solution the mouse was sacrificed and the tumor ex-
cised. The tumor was snap frozen and sent to the
University of Florida packed in dry ice. The tumor was
sliced thin (approximately 0.5 mm) while frozen and 5.0
mL of a 0.1 M DHB in methanol solution was placed on
top of the tumor section and allowed to air dry com-
pletely before analysis.
For the LD/CI experiments, a 7.9 mg piece of frozen
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liver tissue (sliced to approximately 0.5 mm thick) was
placed in a shallow stainless steel well. 4 mL of a 0.1
mg/mL solution of spiperone in 1% aqueous acetic acid
(HOAc) was placed on top of the tissue. The tissue was
allowed to incubate for 1 h and was then washed with
several aliquots of 1% HOAc solution followed by
several aliquots of deionized water. The liver tissue was
then placed on the probe tip and allowed to dry
completely (approximately 1.5–2 h) before analysis. To
determine the amount of spiperone absorbed by the
tissue, LC/MS analyses were performed on the col-
lected wash aliquots and on solvent extracts of similar
liver samples incubated in spiperone. The results of
duplicate experiments indicated that the amount of
spiperone removed in the washings was approximately
equal to the amount absorbed into the liver tissue. For
all experiments, blank tissue samples were analyzed to
assure that there was no carryover of analyte.
Results and Discussion
The top panel (A) of Figure 2 shows the MALDI MS
spectrum (collected on the earlier laser ion trap instru-
ment) of rat liver tissue which had been incubated with
paclitaxel. It can be seen from the spectrum that the
potassium adduct ion at m/z 892 was the most abundant
molecular ion of paclitaxel. The inset for panel (A)
shows a close-up of the region around the [M 1 K]1 ion
at m/z 892 (note that the ions which appear at m/z 857
and 872 are background tissue ions). Nevertheless, the
[M 1 K]1 ion was not readily discernible above the
background tissue matrix noise. With only a single
stage of mass spectrometry, positive identification of
the presence of paclitaxel in the tissue would be impos-
sible at this level. The middle panel (B) of Figure 2
shows the MS/MS daughter ion spectrum of the [M 1
K]1 ion obtained from a different location on the same
sample. For the MS/MS experiments, a 20-D-wide
window around the [M 1 K]1 ion at m/z 892 was
isolated by the forward/reverse scan method [26]. After
isolation, the m/z 892 ion was resonantly excited and
fragmented by CAD. The ion was not isolated to unit
resolution because of the loss of ion intensity associated
with such tight isolation; however, the ion was selec-
tively fragmented to within 1 D on either side of the ion
of interest (see inset of Figure 4B later in this report).
The bottom panel (C) of Figure 2 presents the daughter
ion spectrum of the [M 1 K]1 ion of a paclitaxel stan-
dard. The excellent match between the two daughter
spectra provides positive identification of the drug in
the tissue. The amount of paclitaxel detected was cal-
culated to be less than or equal to 360 fg, based on 0.6 ng
of paclitaxel absorbed by a 10 3 10 3 0.5 mm piece of
tissue during the incubation period and the amount of
tissue ablated by the laser beam (determined by visual
inspection under a microscope to be 100 mm diameter 3
0.1 mm thick).
The success of the above initial studies led to con-
struction of the ion trap laser microprobe instrument in
Figure 1. All of the following experiments were per-
formed on this instrument.
An important step in the evolution of the new ion
trap laser microprobe was the MALDI analysis of a
tissue sample obtained from an in vivo drug study. An
ovarian tumor from an animal which had been dosed
with the drug paclitaxel was analyzed. Our goal in this
study was twofold: to see if MALDI MS/MS could
detect paclitaxel (or any drug compound) in intact
tissue at normal physiological trace levels, and to see if
a preferential location for the compound within the
tumor mass could be detected given the current spot
size (100 mm diameter) and lack of visualization of the
sample in the ion source.
The top panel (A) of Figure 3 shows the MALDI MS
spectrum (an average of 30 laser shots) of the ovarian
cancer tumor after forward/reverse scan isolation of a
50-D-wide window around the [M 1 H]1 ion of pacli-
taxel (m/z 854). Because of the wide window used (again
to keep the sensitivity at a maximum) both the [M 1
H]1 ion (m/z 854) and the [M 1 Na]1 (m/z 876) can be
seen. The [M 1 Na]1 ion was chosen because it typi-
cally represented the most abundant molecular ion
(although the [M 1 H]1 is the most abundant ion in
Figure 2. MALDI spectrum (A) and daughter ion spectrum (B)
for paclitaxel [M 1 K]1 ion from rat liver tissue incubated in a
paclitaxel solution (100 ng) for 1 h. Inset shows a closeup of the
MALDI spectrum around the area of the paclitaxel [M 1 K]1 ion
(m/z 892). Spectrum (C) shows the daughter ion spectrum of the
[M 1 K]1 ion of a paclitaxel standard.
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panel (A), this was not typical for other locations on the
tissue sample). The laser beam was moved to a new
location on the sample and a daughter ion spectrum of
the [M 1 Na]1 ions from another 30 laser shots were
acquired and averaged. The center panel (B) of Figure 3
shows the MS/MS daughter ion spectrum of the [M 1
Na]1 ion of paclitaxel; this spectrum was reproducible
and so could be used for the detection of paclitaxel in
tissue. The daughter ion spectrum of the paclitaxel
[M 1 Na]1 ion from the ovarian tumor shows an
almost identical pattern to that of the daughter ion
spectrum of the [M 1 Na]1 ion of a paclitaxel standard,
as shown in panel (C) of Figure 3. In both cases the
[M 1 Na]1 ion’s intensity was reduced in the daughter
ion spectrum because it has been selectively fragmented
by CAD. Visual inspection of the tumor after analysis
showed that the laser had burned completely through
the tissue (a depth of 0.5 mm). The holes blasted in the
tissue were measured to be approximately 100 mm in
diameter which was estimated to be approximately
0.09% of the total tissue mass on the probe (6.5 mg).
Based on the reported amount of paclitaxel in the tissue
(50 mg/kg), the spectra in Figure 3A, B each represent
approximately 290 pg of paclitaxel detected. The detec-
tion of paclitaxel at physiological trace levels satisfied
our first goal for the ion trap laser microprobe instru-
ment; however, our second goal, the identification of
the location of paclitaxel within the tissue mass, was not
achieved. The thick (DHB) crystal matrix coating on top
of the tissue slice, coupled with the inability to visually
inspect the tissue during analysis, prevented any corre-
lation of acquired spectra with a specific region of the
tissue.
To allow the visualization of the tissue sample sur-
face during sampling (so that spectra could be associ-
ated with a particular location on the tissue), we began
a series of investigations into the use of laser desorption
coupled with chemical ionization (LD/CI). In LD/CI,
the desorption laser is used to vaporize the analyte into
the gas phase as intact neutrals. Ionization of the
analyte occurs separately through ion molecule reac-
tions (including charge exchange, proton transfer, and
proton abstraction) between the desorbed neutrals and
an excess of ionized reagent gas in the ion source.
Typical reagent gas pressures for CI are between 0.1
and 1.0 torr. This pressure is necessary to ensure that
there is a 1000-fold or greater excess of reagent mole-
cules to analyte molecules in the source region. The
advantage of using LD/CI over MALDI for the map-
ping of drug compounds in tissue is that there are no
matrix crystals covering the top of the tissue obscuring
the surface. Also, since the yield of desorbed neutrals
produced from the laser desorption is typically much
greater than the yield of desorbed ions, postchemical
ionization offers the added potential of enhanced sen-
sitivity for trace analysis. LD/CI was first introduced by
Cotter in 1980 in experiments where isobutane reagent
ions were used to ionize a series of glucuronide steroid
neutrals formed by laser desorption [27]. To date, most
of the applications of LD/CI have been for the analysis
of low molecular weight peptides deposited onto solid
substrates [28]. The first application of LD/CI to the
analysis of biological tissues was reported by Perchalski
at the University of Florida using a Finnigan TSQ 45
triple quadrupole mass spectrometer [29]. LD/CI/
MS/MS was used to detect the antiepileptic drug phe-
nytoin (dilantin) from fixed sections of rat liver tissue.
Postchemical ionization was used to prolong the signal
lifetime (from desorbed neutrals) to compensate for the
slow scan speed of the quadrupole mass filter.
For the LD/CI studies, the drug spiperone was
chosen as the target compound. Spiperone, developed
as an antipsychotic drug, belongs to a class of com-
pounds known as azipirones which are similar to
serotonin in structure and so bind to the 5-HT1A recep-
tors in the central nervous system [30]. In vivo neural
recording studies of spiperone have shown that it binds
not only to the 5-HT1A receptors in the brain, but also
binds to 5-HT2 receptors [30]. Because these receptors
are present at various densities throughout the brain,
there is considerable interest in determining the concen-
tration of spiperone in different cerebral regions. Spip-
Figure 3. Spectrum (A) shows the MALDI spectrum for pacli-
taxel in an ovarian cancer tumor after isolation of the region
around the [M 1 H]1 ion at m/z 854. Spectrum (B) is the daughter
ion spectrum of the [M 1 Na]1 ion from a different location on
the same sample. Spectrum (C) is the daughter ion spectrum of the
[M 1 Na]1 ion of a paclitaxel standard.
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erone has been the subject of previous MS studies in our
lab and so has been well characterized [22, 31]. Figure
4A shows the LD/CI daughter ion spectrum of the
[M 1 H]1 ion (at m/z 396) of a spiperone standard.
After isolation (a 5-D-wide window by the forward/
reverse scan method), the [M 1 H]1 ion was frag-
mented by CAD to produce the daughter ion spectrum
shown. The major daughter ions produced are at m/z
165 and 291; daughter ion peaks also appear at m/z 123,
232, and 262.
For the LD/CI studies an IR laser was employed
with more energy per pulse to assure that the tissue
under investigation would be completely desorbed. The
actual energy per pulse of the IR laser was initially so
great (in the 3 J per pulse range) that the ablated tissue
coated the inside of the ion volume, dramatically reduc-
ing ion transmission after a single laser shot. The IR
laser beam was subsequently attenuated, as described
in the Experimental section, and focused down to a spot
with a diameter of 750 mm and an estimated power
density of 4.0 3 107 W/cm2.
Panel (A) of Figure 5 shows the LD/CI spectrum (5
laser shots) of a rat liver tissue slice which was spiked at
a level of approximately 25 mg/kg of spiperone. Note
that the peak at m/z 396, which corresponds to the [M 1
H]1 ion, is completely buried in the tissue matrix noise
(see inset for close-up view of region around m/z 396).
The ion injection time used during the acquisition of
this spectrum was only 90 ms (in contrast to the 4 ms
used in the other LD/CI spectra presented here) to
preserve close to unit resolution. When the tissue was
desorbed with an ionization time of 4 ms without the
isolation of a narrow m/z range, space charging shifted
and broadened the peaks, rendering the spectrum
meaningless. It is obvious from Figure 5 that without
the capability of mass isolation and MS/MS available
with the ion trap, the target drug could not be positively
detected at such low levels. In fact, we found that
LD/CI of tissue produced such intense tissue interfer-
ence ions that the standard forward/reverse scan isola-
tion could not adequately isolate the m/z region of
interest. The tissue matrix ions apparently continued to
fragment during the forward and reverse stages of
isolation (the low mass ions are ejected during the first
step of the two-step isolation), leaving ions at m/z values
below the isolation region (data not shown). Switching
to SWIFT isolation waveforms, which provide axial
modulation at all frequencies around a notched set of
frequencies selected by the operator, overcame these
problems. In this way the higher and lower m/z inter-
fering ions are ejected out of the trap at approximately
the same time. If a higher m/z interferent ion did
fragment during isolation, the daughter ions produced
would still be given sufficient energy to be ejected from
the trap. Each SWIFT waveform isolation burst took
approximately 8 ms (7 bursts per scan were used),
whereas the high mass ejection step of the two-step
isolation technique took 50 ms. This isolation technique
produced significantly better results.
Figure 4. Spectrum (A) shows the laser desorption chemical
ionization (LD/CI) daughter ion spectrum of the m/z 396 ion,
[M 1 H]1, of a spiperone standard demonstrating the fragmenta-
tion pattern following CAD within the ion trap. Spectrum (B)
shows the LD/CI daughter ion spectrum of spiperone from rat
liver tissue. The inset shows that only the ions at m/z 396 and 395
have been fragmented during CAD.
Figure 5. Spectrum (A) shows the LD/CI spectrum of rat liver
tissue spiked with spiperone (MW 395) at a level of 25 mg/kg. The
inset shows an enlargement of a 20-D-wide window around the
[M 1 H]1 ion of spiperone at m/z 396. Spectrum (B) and inset
show the LD/CI spectrum from a different location on the same
sample following a 10-D-wide isolation around the spiperone
[M 1 H]1 ion.
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Panel (B) of Figure 5 shows the LD/CI mass spec-
trum of a new spot on the tissue; this time, however, a
10-D-wide window has been isolated around m/z 396 by
SWIFT waveform isolation. Again, the peak at m/z 396,
which corresponds to the [M 1 H]1 ion of spiperone, is
not the biggest peak in the isolated region of the
spectrum (see inset for close-up of area). To obtain the
LD/CI daughter ion spectrum in Figure 4B, the laser
was moved to a new spot on the tissue; the character-
istic daughter ion peaks at 165 and 291 can be clearly
seen above the background noise, as can daughter ion
peaks at m/z 123, 232, and 262. This daughter ion
spectrum matches the LD/CI daughter ions of the [M 1
H]1 ion of the spiperone standard shown in Figure 4A.
The studies reported here have demonstrated the
ability of MALDI MS/MS and LD/CI MS/MS to detect
and identify drug compounds at physiological levels in
intact tissue samples. The MS/MS capabilities of the
quadrupole ion trap are crucial in performing these
analysis. Future work on this project will include add-
ing an x–y manipulator to the probe. The restriction on
the size of the opening to the ion volume (approximate-
ly 1.0 mm) necessary for optimum CI pressure pre-
cludes the manipulation of the laser beam as it enters
the ion volume. Thus the probe itself will be manipu-
lated (for the LD/CI work presented here the laser spot
was positioned off-center and the probe was rotated to
select a new spot). Additionally, capabilities for visual-
izing the sample during laser desorption will be imple-
mented so that specific locations on the sample can be
selected.
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